Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Clinical Cancer Research - Tập 18 Số 2 - Trang 546-554 - 2012
Harry H. Yoon1, Qian Shi1, William R. Sukov1, Anne E. Wiktor1, Maliha Khan1, Christopher A. Sattler1, Axel Grothey1, Tsung‐Teh Wu1, Robert B. Diasio1, Robert B. Jenkins1, Frank A. Sinicrope1
1Authors' Affiliations: Departments of 1Medical Oncology, 2Health Sciences Research, 3Cytogenetics, 4Anatomic Pathology, 5Cancer Center, 6Laboratory Medicine and Pathology, and 7Gastroenterology, Mayo Clinic, Rochester, Minnesota

Tóm tắt

Abstract Purpose: We examined the frequency, tumor characteristics, and prognostic impact of HER2 protein expression and gene amplification in patients with curatively resected esophageal adenocarcinoma (EAC). Experimental Design: HER2 expression was analyzed by immunohistochemistry (IHC) in surgical EAC specimens (n = 713). Gene amplification was examined by FISH in a large subset (n = 344). Most tumors were T3–4 (66%) or node positive (72%); 95% were located in the esophagus or gastroesophageal junction. No patient received neoadjuvant therapy. Cox models were used. Results: Overall, 17% of EACs were HER2 positive (i.e., IHC3+ or IHC2+ with amplification), with strong agreement between HER2 amplification (HER2/CEP17 ratio ≥2) and expression (κ = 0.83). HER2 positivity was significantly associated with lower tumor grade, less invasiveness, fewer malignant nodes, and the presence of adjacent Barrett's esophagus (BE). EACs with BE had higher odds of HER2 positivity than EACs without BE, independent of pathologic features [OR = 1.8 (95% CI: 1.1–2.8), P = 0.014]. Among all cases, HER2 positivity was significantly associated with disease-specific survival (DSS) in a manner that differed by the presence or absence of BE (Pinteraction = 0.0047). In EACs with BE, HER2 positivity was significantly associated with improved DSS [HR = 0.54 (95% CI: 0.35–0.84), P = 0.0065] and overall survival (P = 0.0022) independent of pathologic features, but was not prognostic among EACs without BE. Conclusions: HER2 positivity was shown in 17% of resected EACs and associated with reduced tumor aggressiveness. EACs with BE had nearly twice the odds of being HER2 positive and, within this subgroup, HER2 positivity was independently associated with improved survival. Clin Cancer Res; 18(2); 546–54. ©2012 AACR.

Từ khóa


Tài liệu tham khảo

Spector, 2009, Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol, 27, 5838, 10.1200/JCO.2009.22.1507

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science(New York, NY), 244, 707, 10.1126/science.2470152

Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169

Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X

Albarello, 2011, HER2 testing in gastric cancer, Adv Anat Pathol, 18, 53, 10.1097/PAP.0b013e3182026d72

Wijnhoven, 1999, Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group, Br J Surg, 86, 529, 10.1046/j.1365-2168.1999.01082.x

Pohl, 2005, The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence, J Natl Cancer Inst, 97, 142, 10.1093/jnci/dji024

Enzinger, 2003, Esophageal cancer, N Engl J Med, 349, 2241, 10.1056/NEJMra035010

Wang, 2008, Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus, Am J Gastroenterol, 103, 788, 10.1111/j.1572-0241.2008.01835.x

Carey, 2006, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 295, 2492, 10.1001/jama.295.21.2492

Miller, 2003, Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia, Clin Cancer Res, 9, 4819

Rauser, 2007, Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues, Clin Cancer Res, 13, 5115, 10.1158/1078-0432.CCR-07-0465

Thompson, 2011, HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival, Ann Surg Oncol, 18, 2010, 10.1245/s10434-011-1554-1

Langer, 2011, Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation, Mod Pathol, 24, 908, 10.1038/modpathol.2011.52

Hu, 2011, HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma, Mod Pathol, 24, 899, 10.1038/modpathol.2011.47

Reichelt, 2007, Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus, Mod Pathol, 20, 120, 10.1038/modpathol.3800712

Heidl, 1993, Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma, J Cancer Res Clin Oncol, 120, 95, 10.1007/BF01200731

Kleinberg, 2007, Chemoradiation in the management of esophageal cancer, J Clin Oncol, 25, 4110, 10.1200/JCO.2007.12.0881

Heidl, 1993, Comparative studies of cardia carcinoma and infracardial gastric carcinoma, J Cancer Res Clin Oncol, 120, 91, 10.1007/BF01200730

Yu, 2009, Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance, J Cancer Res Clin Oncol, 135, 1331, 10.1007/s00432-009-0574-8

Dowsett, 2005, Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer–a study from the IMPACT trialists, J Clin Oncol, 23, 2477, 10.1200/JCO.2005.07.559

Quddus, 2005, HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy, Breast Cancer(Tokyo, Japan), 12, 294, 10.2325/jbcs.12.294

Suntharalingam, 2003, The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996–1999 Patterns of Care Study, Int J Radiat Oncol Biol Phys, 56, 981, 10.1016/S0360-3016(03)00256-6

Yoon, 2010, The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection, Mayo Clin Proc, 85, 1080, 10.4065/mcp.2010.0421

Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x

Perez, 2006, HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial, J Clin Oncol, 24, 3032, 10.1200/JCO.2005.03.4744

Vance, 2009, Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines, Arch Pathol Lab Med, 133, 611, 10.5858/133.4.611

Ruschoff, 2010, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 457, 299, 10.1007/s00428-010-0952-2

Shaheen, 2002, Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review, JAMA, 287, 1972, 10.1001/jama.287.15.1972

Walch, 2000, Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence, Am J Pathol, 156, 555, 10.1016/S0002-9440(10)64760-8

Hardwick, 1995, c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus, J Clin Pathol, 48, 129, 10.1136/jcp.48.2.129

Rygiel, 2008, Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus, Cancer Epidemiol Biomarkers Prev, 17, 1380, 10.1158/1055-9965.EPI-07-2734

van de Vijver, 1988, Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer, N Engl J Med, 319, 1239, 10.1056/NEJM198811103191902

Pradeep, 2011, Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling, Oncogene

Helm, 2005, Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma, Clin Cancer Res, 11, 2478, 10.1158/1078-0432.CCR-04-1280

Alexe, 2007, High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates, Cancer Res, 67, 10669, 10.1158/0008-5472.CAN-07-0539

Pupa, 1996, Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas, J Clin Oncol, 14, 85, 10.1200/JCO.1996.14.1.85

Zell, 2009, Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry, Breast Cancer Res, 11, R9, 10.1186/bcr2225

Reid, 2010, Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis, Nat Rev, 10, 87, 10.1038/nrc2773

Jankowski, 1999, Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus, Am J Pathol, 154, 965, 10.1016/S0002-9440(10)65346-1

Moons, 2005, Barrett's oesophagus is characterized by a predominantly humoral inflammatory response, J Pathol, 207, 269, 10.1002/path.1847

Capello, 2008, Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus, Am J Gastroenterol, 103, 1510, 10.1111/j.1572-0241.2008.01908.x

Chua, 2011, Clinicopathologic factors associated with HER2-Positive gastric cancer and its impact on survival outcomes - a systematic review, Int J Cancer

Bilous, 2010, HER-2 amplification is highly homogenous in gastric cancer, Hum Pathol, 41, 304, 10.1016/j.humpath.2009.10.006

Schoppmann, 2010, Expression of Her-2 in carcinomas of the esophagus, Am J Surg Pathol, 34, 1868, 10.1097/PAS.0b013e3181f8be17

Park, 2011, Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?, Hum Pathol

Barros-Silva, 2009, Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients, Br J Cancer, 100, 487, 10.1038/sj.bjc.6604885

Rice, 2010, Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals, Cancer, 116, 3763, 10.1002/cncr.25146

Thông tin
Thông tin xuất bản

Clinical Cancer Research

Tập 18 Số 2

546-554

Thông tin tác giả